BPC-157 and TB-500 together: is there any evidence for combining them?

The case for stacking BPC-157 with TB-500 rests on a neat story about two peptides doing complementary jobs. Only one study has actually tested the pair against each peptide alone, in 32 rats with repaired Achilles tendons, and the combination added nothing. In people, the entire evidence base is four patients in an uncontrolled knee-pain chart review.

Why people combine them

The argument goes like this. BPC-157 is said to grow new blood vessels into damaged tissue; in cells and rats it raised levels of the VEGFR2 receptor and restored blood flow to an ischaemic limb [4]. Thymosin beta-4, the protein TB-500 is based on, grips actin, the scaffolding cells use to move; its seven-amino-acid actin-binding stretch drove blood-vessel cell migration in lab assays [5]. Supply lines from one, moving cells from the other, so together they should be better than either.

It's a tidy theory. Notice, though, that both explanations end at the same place: new blood vessels and cells moving into an injury. Overlap is at least as plausible as complementarity, and neither mechanism has been measured in a human tendon.

The only head-to-head test

In 2026 a team in Istanbul published the first study we can find that put BPC-157, TB-500 and the combination side by side [1]. They cut and surgically repaired the Achilles tendon in 32 male rats, then split them into four groups of eight.

After four weeks, here is how the groups compared with untreated controls:

The authors state plainly that combined treatment "did not confer additional benefits compared to either agent alone" [1]. They suggest the two peptides may converge on the same downstream pathways, and say that idea still needs testing.

A few cautions before reading much into this. It's one study, in rats, with eight animals per group, and the abstract describes tendons going to either mechanical testing or histology, so some comparisons may rest on fewer animals still. The peptides were injected into the abdomen, not near the tendon or under the skin. Four weeks captures early repair only. And the paper describes its TB-500 as synthetic thymosin beta-4, which leaves open whether it was the seven-amino-acid fragment that the name usually refers to [6] or the full protein. Still, it's the only direct test of the combination, and it didn't support the stacking idea. It is also worth noticing that BPC-157 alone reached significance on none of the three main measures, in a lab outside the Croatian group behind most of the BPC-157 literature.

What exists in humans

Very little. A 2021 chart review from a Florida clinic phoned 16 people who'd had peptides injected into a painful knee [2]. Twelve received BPC-157 alone and 11 of them reported significant improvement. Four received BPC-157 plus thymosin beta-4; three of those four improved and one didn't. There was no control group, no standard pain scale and no imaging, and the knee problems ranged from osteoarthritis to ligament tears. Four patients can't tell you whether a combination beats a single peptide, and the authors didn't claim that.

We found no randomised or even prospective human study of BPC-157 and TB-500 given together. The reviews agree on the wider point: a 2025 systematic review found one clinical study of BPC-157 among 36 in musculoskeletal medicine [3], a 2025 scoping review counted three small human pilot studies across all uses [7], and a 2026 review in Sports Medicine concluded that rigorous human safety data for unapproved peptides, including BPC-157 and TB-500, are scarce [8].

Safety: two unknowns don’t make a known

Combining two compounds that each lack human safety data doesn't average out the risk. It adds a new unknown, the interaction, which nobody has studied. Both peptides are also bought mostly from unregulated sources, so purity and even identity can't be assumed; the 2025 systematic review lists contamination and inconsistent manufacturing among the realistic risks of BPC-157 [3]. Both are banned in sport: BPC-157 under WADA's S0 non-approved substances, thymosin beta-4 and its derivatives including TB-500 under S2 growth factors [9].

What it means in practice

If you read that the pair is "synergistic", that's a hypothesis built from two separate sets of animal and cell studies. Synergy is a specific claim: that the combination does more than the sum of its parts. Showing it needs exactly the design the Istanbul team used, with each drug alone and together against a control, and ideally at more than one dose of each. The single experiment designed to test it found TB-500 did the work in rats and adding BPC-157 changed nothing measurable [1]. That's a thin basis for any conclusion, in either direction, but it is the evidence that exists.

What we still don’t know

• Whether either peptide improves tendon or ligament healing in people. No placebo-controlled human trial of either has reported.
• Whether the rat result holds with larger groups, longer follow-up, local injection or a different injury.
• Which molecule, fragment or full-length protein, the "TB-500" in the rat study actually was.
• Whether the two interact, for better or worse, in any species.

What readers report

First-hand accounts, shared with permission. They are self-reported, not evidence, and sit alongside the research above rather than in place of it.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols